Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 3,020,000 shares, a decline of 26.2% from the May 31st total of 4,090,000 shares. Based on an average daily volume of 1,680,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 7.1% of the shares of the company are sold short.
Shares of Turning Point Therapeutics stock opened at $75.11 on Tuesday. The company’s 50-day moving average price is $50.95 and its two-hundred day moving average price is $40.27. Turning Point Therapeutics has a 52 week low of $23.77 and a 52 week high of $82.20.
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($1.50) EPS for the quarter, missing the consensus estimate of ($1.45) by ($0.05). The business had revenue of $0.40 million for the quarter. During the same period in the previous year, the firm earned ($0.73) EPS. The company’s revenue for the quarter was down 98.4% compared to the same quarter last year. As a group, analysts predict that Turning Point Therapeutics will post -6.85 earnings per share for the current year.
A number of research firms have commented on TPTX. Wedbush downgraded shares of Turning Point Therapeutics from an “outperform” rating to a “neutral” rating and lifted their price objective for the stock from $61.00 to $76.00 in a report on Friday, June 3rd. Bank of America assumed coverage on shares of Turning Point Therapeutics in a report on Friday, May 20th. They set a “buy” rating and a $58.00 price target for the company. Guggenheim set a $76.00 price target on shares of Turning Point Therapeutics in a report on Monday, June 20th. SVB Leerink downgraded shares of Turning Point Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $101.00 to $76.00 in a report on Monday, June 13th. Finally, Wells Fargo & Company cut shares of Turning Point Therapeutics from an “overweight” rating to an “equal weight” rating and set a $76.00 price objective on the stock. in a research note on Friday, June 3rd. Nine investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $78.22.
Turning Point Therapeutics Company Profile (Get Rating)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Hello Group Stock is Attractive Value Speculators
- PVH Corp Stock Approaching Key Support Levels
- PetVivo Holdings Is A Growth Stock Worth a Look
- Two Pet Health Stocks To Watch And One To Avoid
- 5 Reasons to Climb Aboard Carnival Stock
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.